Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36476495)

  • 21. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 22. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
    Capparelli C; Rosenbaum S; Berger AC; Aplin AE
    J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
    Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
    Knauf JA; Luckett KA; Chen KY; Voza F; Socci ND; Ghossein R; Fagin JA
    J Clin Invest; 2018 Aug; 128(9):4086-4097. PubMed ID: 29990309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RHOA activity in expanding blastocysts is essential to regulate HIPPO-YAP signaling and to maintain the trophectoderm-specific gene expression program in a ROCK/actin filament-independent manner.
    Marikawa Y; Alarcon VB
    Mol Hum Reprod; 2019 Feb; 25(2):43-60. PubMed ID: 30395288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
    Xing J; Liu R; Xing M; Trink B
    Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
    Bonaldi E; Gargiuli C; De Cecco L; Micali A; Rizzetti MG; Greco A; Borrello MG; Minna E
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072194
    [No Abstract]   [Full Text] [Related]  

  • 36. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
    Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
    Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
    Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
    Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
    Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
    Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.